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 3 
Abstract 
Progress in sequencing technology is intrinsically linked to progress in 
understand cancer genomics. This review aims to discuss the development 
from Sanger sequencing to next generation sequencing (NGS) technology. 
We highlight the technical considerations for understanding reports using 
NGS. We discuss the findings of studies in head and neck cancer using NGS 
as well as the Cancer Genome Atlas. Finally we discuss future routes for 
research utilising this methodology and the potential impact of this. 
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 4 
Introduction 
 
Progress in cancer research has paralleled that of progress in the various 
technologies that can be utilised and exploited. One of the most remarkable 
developments in the last decade has been the advent of next generation 
sequencing (NGS) technology. The human genome sequence was published 
in 20011, 2. This ushered in a new era of scientific research, in which the 
correlation between genomic and phenotypic characteristics of disease could 
be made in new and promising ways. 
 
Fearon and Vogelstein demonstrated that morphological development of 
colorectal cancer occurs in parallel with a stepwise progressive accumulation 
of genetic alterations3. Califano et al created a similar model for the genetic 
basis of head and neck cancer4. Since these landmark papers, one of the key 
theories driving cancer research has been that studying genetic changes 
across the entire genome (genomics) to identify alterations responsible for 
carcinogenesis and metastasis, could lead to new therapies and insights into 
how to manage patients with cancer.  
 
The aim of this review is to explain the technological advances in sequencing 
and review their impact and discoveries thus far in head and neck cancer as 
well as discuss potential for the future. 
 
Sanger sequencing 
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 5 
Sanger et al described Sanger sequencing in 19775. This involved the 
copying of a template strand of DNA into radiolabelled complementary DNA 
(cDNA) strands. The synthesis of these strands is randomly terminated, and 
the sequence reconstructed from the final base of each strand5-7.  
 
The first genome to be sequenced was that of the bacteriophage phi X 174 
(ΦX174)8. This utilised Sanger technology to identify the 5386 nucleotides. 
Sanger sequencing is accurate but can only sequence DNA fragments up to 
1,000 bp in length. This would need to be performed 3 million times in order 
sequence the human genome once. For limited sequencing, however it is very 
cheap.  
 
A progression in the rate of sequencing was achieved with Shotgun Sanger 
sequencing. This utilised plasmid cloning to produce cDNA fragments for 
sequencing, allowing longer overall templates of DNA to be sequenced more 
rapidly. The first cellular organism genome to be published was Haemophilus 
influenza in 19959. This utilised Shotgun sequencing to reveal the 1,830,140 
base pairs. Shotgun sequencing was key in increasing the speed at which 
DNA could be sequenced, and was the workhorse approach that produced 
the first draft of the human genome1.  
 
In addition to the laborious techniques and short sequences, Sanger 
sequencing was also limited in the accuracy of the first 40 and last 100 bases 
to be sequenced due to primer binding. The accuracy is also affected by 
increasing levels of guanine-cytosine (GC) content in the DNA strands to be 
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sequenced. Similarly, repetitive regions of DNA could also affect accuracy of 
sequencing10. Though shotgun sequencing did enhance the rate of 
sequencing, and latterly this became more automated, it still suffered similar 
issues6. 
 
Next generation sequencing 
 
This describes a technology that differs from Sanger sequencing and 
represents a huge step forward in terms of speed of sequencing. It is 
important to understand that next generation sequencing (NGS) does not 
automatically mean whole genome sequencing (WGS) or exome sequencing 
(see table 1). It is a technology as opposed to a specific application.  
 
NGS involves the breaking up of a DNA sample into many millions of 
fragments of known average length (see figure 1). Synthetic DNA “adaptors” 
are then bound to these fragments and labelled with an index primer (these 
are then referred to as DNA “libraries”). These fragments are then bound to a 
support matrix where an amplification reaction takes place followed by cycles 
of sequencing, which occur in parallel (leading to the term massively parallel 
sequencing). Signals are detected according to the nucleotides sequenced. 
Each DNA strand sequenced is termed a read. NGS has the capacity to 
produce hundreds of millions of reads. These are generally short (50 – 200 
bases) and the huge numbers of reads requires considerable specialised 
computer resources to align these to the reference genome. The number of 
times the same area the genome is sequenced is referred to as depth (or 
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coverage) of sequencing. To produce more reliable data the same area needs 
to be sequenced many times according to the type of information required. 
For instance, whole genome sequencing requires higher coverage compared 
to copy number variation sequencing. There are however different platforms 
with variations in their chemistry. Each of these platforms can be used for 
sequencing DNA or RNA (see table 2). 
 
Roche  
The Roche GS-FLX 454 Genome Sequencer was the first commercially 
available platform (2004). These use an emulsion of beads as the matrix to 
which DNA libraries are bound. The amplification process ensures 
approximately 1 million copies of the same DNA fragment are bound to each 
bead. Nucleotides are then added and cDNA stands are synthesised via a 
pyrophosphate reaction (therefore this is often referred to as pyrosequencing). 
This reaction produces a light signal proportional to the nucleotides detected 
by a camera and converted to sequencing “reads” by a computer11. The use 
of this to sequence an individual’s complete genome was published in 200812.  
This represented a huge drop in the cost of sequencing a person’s genomes 
(less than $1 million compared to more than $100 million by Venter et al)1, 12. 
Compared to other NGS platforms the Roche 454 is fast (23 hrs) and 
produces long reads (up to 1000 bp), though it cannot produce as many reads 
(therefore Roche data is low in depth). There is also a benchtop version (the 
Roche GS Junior). 
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More importantly, Roche announced in 2013 that it plans to shut down 
production of the 454 platform, though it will continue supporting current 454 
sequencers already in use until 2016. 
 
Illumina 
The Illumina HiSeq uses a specialised glass slide called a flow cell as the 
matrix to which adaptor-ligated DNA is bound13. These fragments are then 
amplified to form clusters of identical DNA fragments. Fluorescent-labelled 
nucleotides are added to allow sequencing-by-synthesis and the signal 
released measured by a camera and translated to sequencing reads. This 
platform produces much more data than the Roche 454 in terms of depth of 
reads, though this does require experienced bioinformatics support. On high-
output mode it takes two weeks to run, though this can be modified.  A 
cheaper, quicker model (MiSeq) can be used for targeted sequencing of a 
smaller region of the genome14. Illumina have also introduced both benchtop 
HiSeq version and a larger machine to widen options in terms of cost and 
throughput. 
 
Life Technologies 
The Supported Oligonucleotide Ligation and Detection (SOLiD) platform uses 
magnetic beads to bind DNA libraries and undergo amplification by PCR. Four 
fluorescently labelled probes are added and ligate to the DNA library strands 
in a cyclical manner producing a signal, which is read by a camera. This is 
very precise in reading bases (99.99% accuracy) and produces good depth of 
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reads, but can be relatively prone to errors due to technical issues preparing 
the libraries and running the system11, 14.  
 
Life Technologies also produce the Ion Personal Genome Sequencer (PGM). 
This utilises semiconductor technology (ion torrent technology) in a similar 
fashion to pyrosequencing. Known nucleotides are introduced and hydrogen 
ions are released if they are added to the cDNA strand. These produce a pH 
change, which is detected and proportional to the number of bases added14, 
15. 
 
Single Molecule Sequencing 
This involves sequencing single molecules of DNA without any amplification. 
The advantages of this are removal of any potential bias or inaccuracy 
produced by the amplification step, as well as potentially increased accuracy, 
speed of sequencing and reduced cost14, 16, 17. The Helicos Heliscope system 
is still based on sequencing-by-synthesis and fluorescence detection16. 
Oxford Nanopore Technologies is developing a system of single molecule 
sequencing utilising a lipid bilayer, porous membrane that DNA molecules 
adhere to and then pass through on application of an electric current17. The 
passage of different bases through a pore produces alterations in the current 
across the membrane, which is measurable18. 
 
This type of sequencing is sometimes referred to as third generation 
sequencing, and accuracy of these platforms is still under investigation.  
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Technical Considerations 
 
In addition to the different platforms there are several technical considerations 
to understand in the production and analysis of NGS data. 
 
Laboratory 
The source of the nucleic acid is important. Cell lines, fresh tissue and 
formalin-fixed paraffin embedded (FFPE) tissue are all potential sources. Cell 
lines can enable replicable results though genomic differences between cell 
lines and primary human cells have been described19. Fresh tissue is a good 
source of high quality nucleic acid, though can be more time-consuming to 
obtain. The archives of FFPE tissue around the world present huge potential 
in terms of numbers of samples. They also offer the advantage that follow-up 
data is often more easily and rapidly available for these samples. This nucleic 
acid is degraded and can be more challenging to work with as well as 
containing artefacts from the formalin-fixation process20. Techniques have 
improved so that FFPE tissue is increasingly being used21, 22.  
 
The purity of the source cell type is important. Tumour samples frequently 
contain mixed populations of cancerous epithelial cells, normal epithelium, 
lymphocytes and stromal cells. These non-cancerous, non-epithelial cells also 
contain nucleic acid, which can create “noise” masking the signal of the target 
cell. Previously, a minimum of 70% tumour cell fraction had been thought of 
as necessary, though with NGS this issue can be tackled a number of ways. 
By increasing the depth of sequencing, anomalies that are only present in a 
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smaller fraction of the cells being sampled can be detected23. The HNSCC 
samples used by the Cancer Genome Atlas (TCGA) had a median tumour cell 
fraction of ~50% and it is likely that much lower fractions will still yield very 
useful information24. This issue can also be accounted for with the 
development of algorithms that can enable lower fraction genomic anomalies 
to be identified, even with lower numbers of reads25.  
 
Cost 
Sequencing costs have dropped dramatically since 2001, as shown in figure 
2. This data from the National Human Genome Research Institute (NHGRI) 
compares DNA sequencing costs to a hypothetical trend described by 
Moore’s Law (this predicts the trend of doubling in computing power 
associated with a decrease in hardware costs)26.  
 
Bioinformatics 
Though the costs of sequencing a sample of DNA have reduced considerably, 
the data produced requires varying amounts of analysis. This is a challenging, 
specialised skill. Both academic and commercial institutes, with an interest in 
NGS are currently investing heavily in bioinformaticians. This cost is often not 
accounted for in claims of the “$1,000 genome”27.  
 
Bioinformatics is key in the analysis of NGS data and in accounting for 
potential error. Sources of error in NGS include PCR artefact. Many NGS 
methodologies involve one or more PCR steps, during which errors in PCR 
replication can cause mismatches in the alignment to the reference genome, 
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causing essentially a false positive. Similarly PCR steps inevitably produce 
duplicates of the same segments of nucleic acid. These waste sequencing 
reads and if there are excessive amounts reduce the accuracy of sequencing 
overall28, 29. Inaccuracy in the sequencing platform calling (recognising) bases 
is also an issue. This is referred to as sequencing error and varies in reports 
from 1 in 1000 bases to 1 in 10,000,000 bases30, 31. Though these appear low, 
given the billions of bases sequenced with each run this is significant. 
Attempts to reduce this error include increasing read depth (the number of 
times each DNA strand is sequenced), using technical replicates (sequencing 
the same library repeatedly to identify error) and biological replicates (multiple 
samples from the same cell type to identify random errors and repetitive 
abnormalities)28, 32.  
 
The primary aim of the bioinformatician is to process and analyse the raw 
NGS data with accurate ‘calling’ of anomalies (whether mutation, copy 
number etc) and minimising the rate of false positives. The degree of variation 
for cancer genomes compared to the reference genome varies considerably. 
Adjustments must therefore be made for the sample’s background anomaly 
rate, ploidy and purity23. For example if a sample contained 50% tumour DNA 
and a mutation is present on one arm of a triploid chromosome, this will only 
be present in 16.6% of the sequenced reads23. The depth of sequencing will 
influence the ability to detect a mutation such as this as will the presence of a 
matched normal sample, also sequenced at sufficient depth.  An error can be 
made due to detecting a germline event in the tumour and failing to detect it in 
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the normal or when a mutation is mistakenly called in the tumour when both 
the tumour and normal are wild-type23, 25.  
 
The presence of important low frequency mutations in clonal subpopulations 
within the sample is another confounding issue. Sequencing depth and the 
use of algorithms that are stable in the presence of data from genomically 
heterogeneous tumours such as HNSCC is essential. 
 
New methods of analysing NGS to produce more accurate results or to 
discover clinically relevant patterns are produced every month33-35. Much of 
this data is essentially open source and available for download e.g. CNAnorm, 
a programme available from Bioconductor.org designed to estimate copy 
number aberrations in cancer samples36. Considerable effort is required to 
keep abreast of these as well as the ongoing results of sequencing being 
published. 
 
Specifically for head and neck cancer, the Mutant Allele Tumour 
Heterogeneity algorithm (MATH) was developed to measure intratumour 
heterogeneity from publically available exome sequencing data37, 38. A higher 
MATH measure was found to be associated with specific groups of head and 
neck cancer with poorer outcome (those with TP53 mutations, HPV-negative 
and HPV-negative tumour with increased smoking pack-year history)37.  
 
NGS and head and neck cancer 
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The first major studies in the use of NGS in HNSCC were published in 201138, 
39. These two studies together performed whole exome sequencing on 106 
patients with HNSCC in total. These included oral, oropharyngeal, laryngeal, 
hypopharyngeal and sinonasal tumours. It also included HPV-positive and 
negative tumours. These studies confirmed the findings of previous genomic 
work that TP53 was the most commonly mutated gene in HNSCC and also 
discovered the second most commonly mutated gene was NOTCH1 (in 
around 15% of patients)38, 39. This was the first time NOTCH1 had been 
implicated in HNSCC. 
 
Interestingly these studies also found that HPV-positive tumours had 
approximately half the mutation rate of HPV-negative tumours38, 39. On 
analysing subgroups they also found smokers had a higher rate of guanosine 
to thymidine point mutations, in addition to having a higher rate of mutations. 
In general they found around 130 mutated genes per sample. The surprisingly 
low proportion of recurring mutations could be related to the mix of subsites 
reducing the number in each group, but gives a picture that each head and 
neck tumour is genomically quite different to the next. 
 
In a follow up publication by Lui et al in 2013 a further 45 tumours had 
undergone whole exome sequencing, making a total of 151 sequenced 
tumours available for analysis40. Again a large number of mutated genes were 
identified per sample and a high degree of inter-tumour mutational 
heterogeneity observed. Developing their analysis, they focused on specific 
functional pathways that had previously been identified as targetable in 
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cancer. By doing this they found 31% of HNSCC in their cohort contained 
phosphoinositide 3-kinase (PI3K) pathway mutations. This signalling axis has 
been shown to have a role in cancer cell growth, survival, motility and 
metabolism41-43. Lui et al found that PI3K-pathway mutated HNSCC contained 
a higher rate of mutations in known cancer genes and that those with 
concurrent mutations in PI3K pathway genes were all advanced tumours 
implicating his pathway in HNSCC progression40. This study highlighted the 
potential for NGS to identify therapeutic targets and biomarkers in HNSCC. 
 
Integrative genomics is a burgeoning research area and the combination of 
NGS data with other techniques was demonstrated by Pickering et al who 
used exome sequencing in 40 OSCC patients with SNP array copy number 
data, gene expression and miRNA expression as well as DNA methylation. 
They identified four major driver pathways in OSCC including mitogenic 
signalling, Notch, cell cycle and TP53. Though a small group they also 
highlighted two subgroups defined by the key genes FAT1 and CASP823. This 
approach also identified currently and potentially targetable genomic 
anomalies.  
 
The TCGA has performed comprehensive genomic analysis of 279 untreated 
HNSCC cases44. This included whole exome sequencing, whole genome 
sequencing and whole transcriptome sequencing as well as miRNA, DNA 
methylation and copy number profiling. Thirty-six of the tumours were HPV-
positive and 243 were HPV-negative. The majority of tumours were oral cavity 
and laryngeal (n = 244/279, 87%). Of 33 oropharyngeal tumours they found 
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64% were HPV-positive, whilst only 6% of non-oropharyngeal tumours were 
HPV-positive44.  
 
The TCGA found HPV-positive and negative tumours to have an overall 
different mutation profile, with HPV-positive tumours exhibiting infrequent 
mutations in TP53, CDKN2A, FAT1 and AJUBA. They found 86% of HPV-
negative tumours harboured TP53 mutations whilst only 1 of 36 HPV-positive 
tumours had a TP53 mutation. Whilst PIK3CA was found to be mutated in 
both HPV-positive and negative tumours, a specific mutation of the helical 
domain of PIK3CA was predominant in HPV-positive tumours – an important 
finding when considering targetable events. EGFR was found to be rarely 
mutated in HPV-positive tumours compared to HPV-negative tumours44. This 
could have serious implications regarding the use of EGFR-inhibitors in these 
patients.  
 
The larger numbers involved in the TCGA do lend a greater credence to their 
ability to analyse subgroups. They confirmed previously reported gene 
expression subtypes (atypical, mesenchymal, basal and classical)44-46. Using 
an integrated approach they were able to identify genomic markers and 
suggest pathways associated with each subtype.  
 
The India Project Team of the International Cancer Genome Consortium 
(ICGC) demonstrated the advantages of concentrating resources and 
collaborative efforts by reported whole exome sequencing on 50 gingivo-
buccal SCC (GBSCC) and targeted resequencing on a further 60 GBSCC24. It 
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is vital that genomic patterns identified in different cohorts of HNSCC are not 
mistakenly assumed to be present in another. The prevalence of betel quid 
chewing in South-East Asia means a different profile of HNSCC is seen in this 
region. This study identified 5 new genes associated with GBSCC and 3 
molecular subgroups demonstrating different disease-free survival. 
 
Increasingly, important therapeutic subgroups of patients with HNSCC will be 
discovered as the numbers of tumours being sequenced grows. This is 
important in the effort towards “personalised medicine”. Part of the revolution 
being driven by NGS will be the shift away from purely classifying tumours by 
pathologic criteria and integrating genomic subgroups that are clinically 
relevant and will guide treatment decisions. Gross et al took advantage of the 
TCGA data available (WES, copy number variation, mRNA and miRNA 
expression) and combined 250 HPV16 negative cancers, aged under 8525. 
They were able to link loss of 3p with TP53 mutation as a marker for 
significantly decreased survival (1.9 yr compared to >5 yr for TP53 mutation 
alone). They also identified mir-548k expression as an additional marker for 
further reduced survival.  
 
Another study performed whole exome sequencing on 16 younger non-
smokers with oral tongue cancer (<45 years old) and 28 older smokers48. 
Surprisingly, this study found the two groups to be genomically similar. On 
interrogating TCGA data for lung adenocarcinoma, bladder urothelial 
carcinoma and HNSCC, a smoking mutation signature was generated. Both 
young and older oral tongue cancers were found to be most similar to a non-
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smoking mutation profile. Admittedly this is a small group of uncommon 
cancers but the combination of individual study data with TCGA data is a 
good example of the accumulative power of NGS. 
 
Targeted sequencing could also be useful in confirming a cell line mutational 
profile when attempting to demonstrate in vitro efficacy of targeted therapies, 
though if course the lack of epigenetic factors must be borne in mind49.  
 
NGS also has applications for the determination of HPV-status. This 
technology can be used to detect copies of HPV DNA within the sample being 
sequenced. It also has the advantage that all sub-types of HPV can be 
screened for simultaneously50. This can be achieved with low-coverage and 
relatively low-cost NGS technology and can be performed as an additional 
analysis of the same sequencing data being obtained for other purposes at no 
extra cost. Issues with the use of this technology relate to the fact that 
detection of a single copy of HPV DNA within the sample does not mean the 
tumour was driven by HPV and there is no accepted standard for the number 
of detectable copies that should be regarded as a positive result. Work in 
cervical cancer certainly shows promise for a NGS based high risk HPV 
genotyping assay51. Conway et al found NGS to be comparable to PCR and 
p16 immunohistochemistry with excellent specificity50. It has also been used 
to screen a large number of oral verrucous carcinoma samples for all 
subtypes of HPV establishing the scarcity of HPV in this type of oral cancer52.  
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RNAseq has also been used to evaluation HPV16 expression in seven young 
patients (average age 37) with oral tongue tumours53. This study found that 
these patients had a poor prognosis and found no evidence of HPV16 
expression. Seiwert et al compered targeted exome sequencing and copy 
number profiles of 51 HPV16 positive and 69 HPV16 negative tumours. They 
found a similar overall mutational burden in both groups though unique 
mutations in DDX3X and FGFR2/3 were found in HPV16 positive tumours44.  
 
Parfenov et al used NGS to investigate the tumour-host interaction in HPV16 
positive HNSCC45. They examined whole genome sequencing and DNA 
methylation profiles in 35 HPV positive tumours and compared these to 270 
HPV16 negative samples from the TCGA cohort. Whole genome sequencing 
allowed them to identify sites of integration of HPV DNA into the host genome. 
By doing this they were able to identify cancer genes at the sites of integration 
that were potentially disrupted and involved in the carcinogenic mechanism in 
virally driven HNSCC. 
 
The issue of intra-tumour heterogeneity has gained increasing prominence 
recently with landmark studies in renal cell carcinoma using NGS to 
demonstrate clearly significant mutational difference in different samples from 
the same tumour54, 55. The potential impact of this on the use of genomic 
biomarkers to guide treatment and clinical trials is huge. Three samples from 
a single oropharyngeal tumour and two samples from its corresponding 
cervical metastasis underwent whole genome sequencing in a study by Zhang 
et al56. This found only 41% of all somatic point mutations were shared across 
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all five samples. Though this concurred with larger studies clearly the high 
cost and singular workload in applying this technology is demonstrated with 
only the ability to analyse one tumour. This cost is continuing to come down 
but CNVseq or targeted sequencing of a smaller panel of known genes could 
be used to demonstrate genomic heterogeneity at lower cost. 
 
Conclusion 
 
NGS technology has revealed significant genomic characteristics of HNSCC. 
The technology available is advancing continually as are the methods for 
analysing the data produced. In light of this, it is important for raw NGS data 
obtained by different groups to be made publicly available after publication. 
The ability to add to the pool of data is vital for tumours that are less common 
such as HNSCC. The issue of subsite signatures and subgroups according to 
ethnicity, inheritance, HPV and smoking amongst others is also a reason to 
try and pool data in order to increase the power of available data. Projects 
such as Head and Neck 5000 present a fantastic opportunity for large 
numbers of tissue and blood to be interrogated, though these attempts need 
to be carefully planned to avoid wasting resources57. 
 
Precancer in HNSCC still requires analysis using NGS technology with 
comparison to spatially and temporally-related cancer in order to help divine 
tumour promoters and drivers. 
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Since the first draft of the human genome was produced the cost of whole 
genome sequencing has dropped from approximately a billion dollars to a 
couple of thousand dollars. The speed at which this data can be obtained has 
gone from years to two weeks. Advancements will continue to be made to 
improve accuracy and data processing. The information gleaned from NGS 
will be collated and combined with clinicopathologic data on an increasingly 
large scale. Combining NGS with other genomic approaches on a large scale 
will reveal biomarkers and therapeutic targets. This will enable the 
development of clinically–relevant, molecular sub-groups that will guide 
treatment.  
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Figure 1: Above is shown the processing nucleic acid into a form for next 
generation sequencing. (1) The genomic DNA has been extracted from the tissue 
sample. (2) This is then broken down into fragements of approximately equal 
maximum length. This is necessary as NGS produces sequencing reads of a fixed 
maximum length, dependent on the platform and settings. (3) + (4) Adaptor 
sequences and primers are ligated to the fragmented DNA in order for this to 
bind to the sequencing matrix and for each strand to be identifiable when 
analysing the reads in the subsequent data. (5) The labelled DNA binds to a 
sequencing matrix and each strand undergoes an amplification process 
producing clusters which are all read many times, thus improving the accuracy 
of the sequencing. In the Illumina platform the matrix takes the form of a glass 
slide as shown above though this can take the form of bead, as in the Roche 
platform. (6) Nucleotides are added and cDNA strands are synthesised from 
these. A laser is used to make the nucleotides fluoresce. This signal is detected 
and converted into sequencing reads.  
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Figure 2: Illustration of the reduction in DNA sequencing costs (dotted line) 
since 2001 compared to a hypothetical trend dictated by Moore’s Law (solid 
line). Reproduced with kind permission from KA Wetterstrand, DNA 
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Sequencing Costs: Data from the NHGRI Genome Sequencing Program 
(GSP) Available at: www.genome.gov/sequencingcosts. Accessed 18/12/14. 
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Term Source Material Information obtained 
Whole Genome 
Sequencing 
DNA Entire DNA sequence  
Whole Exome 
Sequencing 
DNA Sequences of all 
known exons for known 
genes  
Whole Transcriptome 
Sequencing (RNASeq) 
RNA Sequence of all RNA 
molecules contained in 
the sample  
Targeted sequencing DNA/RNA Sequence of a subset 
of genes of identified 
region of the genome 
microRNA Sequencing 
(miRNASeq) 
microRNA Sequences of all 
known miRNAs 
Copy Number Variation 
Sequencing (CNVSeq) 
DNA Areas of gain or loss in 
copy number of the 
genome 
 
Table 1: Different type of sequencing performed with NGS technology 
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Platform Underlying 
mechanism 
Read 
length (bp) 
Data 
output/run 
Time/run Advantages Disadvantages 
Roche 454 Pyrosequencing 700 0.7 Gb 24 hr Fast  
Longer read length 
High reagent cost 
Higher error rate in 
repetitive regions 
Illumina HiSeq Sequencing by 
synthesis 
36 - 100 600 Gb 27 hr - 
10 days 
Higher data yield/run,  
Higher throughput,  
Cost effective in terms 
of data yield 
Short read length 
Longer run time 
SOLiD  (Life 
Technologies) 
Sequencing by 
ligation 
35 – 75 180 Gb 7 day to 
2 weeks 
High accuracy 
Very high throughput 
Long run time 
Short read length 
Complex sample 
preparation 
Ion Torrent (Life 
Technologies) 
Sequencing by 
synthesis 
200 1 Gb 2 – 4 hr Fast 
Low cost 
 
Lower data yield 
High error rate in repetitive 
regions 
Short read length 
 
Table 2: Comparison of currently available NGS platforms 
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